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Background & Aims: Nonalcoholic chronic pancreatitis
is usually idiopathic and often associated with cystic
fibrosis gene (CFTR) mutations. It is unknown whether
pancreatitis risk correlates with having 1 or 2 CFTR
mutations, abnormal epithelial ion transport, or muta-
tions of other genes. Methods: We tested 39 patients
with idiopathic chronic pancreatitis (mean age at diag-
nosis, 33 years) for common mutations of CFTR and of
genes encoding a trypsin inhibitor (PSTI) and trypsino-
gen (PRSS1). To exclude hereditary pancreatitis, we ini-
tially relied on family history and subsequently tested for
PRSS1 mutations. Twenty subjects were tested for rare
CFTR mutations (DNA sequencing) and 11 were tested
for extrapancreatic CFTR function (clinical and physio-
logic evaluation). Results: Mutations were identified in
24 of 39 subjects. Nine patients had cystic fibrosis–
causing mutations, 8 of whom also had mild-variable
mutations. Eight others had only mild-variable muta-
tions. Nine subjects had the N34S PSTI mutation and 1
had hereditary pancreatitis (R122H, PRSS1). Pancreati-
tis risk was increased approximately 40-fold by having 2
CFTR mutations (P < 0.0001), 20-fold by having N34S
(P < 0.0001), and 900-fold by having both (P <
0.0001). Subjects with 2 CFTR mutations had abnormal
nasal epithelial ion transport and clinical findings sug-
gesting residual CFTR function between that in cystic
fibrosis and in carriers. By contrast, subjects with only
PSTI mutations had normal CFTR function. Conclusions:
CFTR-related pancreatitis risk correlates with having 2
CFTR mutations and reduced extrapancreatic CFTR func-
tion. The N34S PSTI mutation increased risk separately.
Testing for pancreatitis-associated CFTR and PSTI geno-
types may be useful in nonalcoholic pancreatitis.
Nonalcoholic chronic pancreatitis commonly leads torecurrent abdominal pain, pancreatic insufficiency,
and life-threatening complications.1 Even though nonal-
coholic chronic pancreatitis is usually idiopathic and
sporadic,2,3 recent studies have associated this condition
with mutations in CFTR, the gene that causes cystic
fibrosis (CF).4,5
It is unknown whether pancreatitis risk is mainly
associated with having 1 or 2 CFTR mutations. This is
important because CF carriers (with 1 CF-causing mu-
tation) represent 3%–4% of the general population.
Combining the data from several recent studies, 18% of
individuals with idiopathic chronic pancreatitis had
common CF-causing mutations, whereas only 2% were
recognized as compound heterozygotes who had both a
milder CFTR mutation and a CF-causing mutation.4–9
We suspected that these published studies underesti-
mated the frequency of CFTR compound heterozygotes
in pancreatitis because they did not comprehensively test
for rare CFTR mutations. Thus, one goal of this study
was to perform more detailed genetic testing to deter-
mine the prevalence of rare CFTR mutations in individ-
uals who would have been classified as CF carriers based
on routine genetic testing.
It is also unknown whether other genes modify the
risk of CFTR-related pancreatitis. Mutations in the pan-
creatic secretory trypsin inhibitor gene (PSTI or SPINK1)
have recently been associated with childhood pancreati-
tis.10,11 Because PSTI expression is acinar12 and CFTR is
ductular,13 we anticipated that these genes might inde-
pendently influence pancreatitis risk. If so, then testing
for PSTI mutations might identify a subset of CF carriers
in whom the risk of pancreatitis is especially high.12,14
To better define the link between CFTR mutations
and pancreatitis risk, we performed detailed testing on a
series of patients with idiopathic chronic pancreatitis.
The series includes subjects from our prior report4 plus
additional subjects recruited using similar criteria. We
Abbreviation used in this paper: CF, cystic fibrosis.




examined them for rare CFTR mutations, for PSTI mu-
tations, and for clinical and physiologic evidence of im-
paired extrapancreatic CFTR function. By correlating
pancreatitis risk with reduced CFTR-mediated ion trans-
port and related clinical features, this analysis has impli-




Our prior study examined 27 subjects who were iden-
tified by reviewing charts of patients referred to Duke Uni-
versity Medical Center from 1991 to 1996, as described.4
Briefly, each subject was white and had multiple episodes of
abdominal pain with objective evidence of pancreatitis; we
excluded patients with moderate alcohol use (over 15 drinks/
week at any time), hereditary pancreatitis by family history, or
CF lung disease.4 When subsequent genetic testing diagnosed
hereditary pancreatitis15 in 2 of the initial report’s subjects
(nos. 11 and 15),4 we recontacted them to further review their
family histories and recognized that 1 case (no. 15) should have
originally been excluded on this basis; therefore, 26 subjects
from the prior report4 met the original entry criteria and were
included in this series. In subsequent chart reviews, we focused
on younger patients (diagnosed by age 50 years) and we
screened potential new subjects for PRSS1 mutations before
entry to avoid diluting the series of idiopathic cases with
individuals who have hereditary pancreatitis. Using these
modified entry criteria for pancreatitis patients seen at this
medical center, 8 additional subjects were enrolled and 3
candidates were excluded because they had the R122H PRSS1
mutation; the family histories were negative for the 3 excluded
candidates. In addition, we enrolled 3 patients who were
referred from outside centers who met these entry criteria.
Two additional patients were tested who were referred from
outside centers as known CF carriers with unexplained pan-
creatitis, nondiagnostic sweat tests, and normal chest radio-
graphs. They were tested for rare CFTR mutations and for
mutations of other genes; also, 1 of these subjects underwent
clinical and physiologic evaluation studies (see below). They
were excluded from the series for most prevalence ratio calcu-
lations because they were known to be CF carriers before
referral. Thus, the full series contained 39 subjects, but most
prevalence calculations were based on data for only 37 subjects.
Table 1 summarizes how subgroups of subjects were recruited
and tested.
Molecular Analyses
All subjects were screened for 17 CFTR mutations
(including 5T) as described4 and were tested for D1152H by
restriction enzyme digestion. In 20 subjects, including all 13
subjects with only one mutation detected by screening, we
sequenced all CFTR exons and flanking regions (ABI310
Genetic Analyzer; Applied Biosystems, Foster City, CA). The
sequenced group included 4 subjects with normal CFTR ge-
notypes (by screening) who were selected based on their will-
ingness to undergo physiologic testing (see below). Sequencing
was not done in others with normal CFTR genotypes (by
screening) because of cost.
We defined severe alleles (CFsev) as those causing CF by
current consensus criteria16; they cause classic CF in homozy-
gotes (CFsev/CFsev) and in compound heterozygotes who also
have DF508 (DF508/CFsev). Mild-variable alleles (CFm-v) cause
variable phenotypes (e.g., congenital bilateral absence of the
vas deferens) in compound heterozygotes with CFsev alleles
(CFsev/CFm-v). CFm-v includes mutations that sometimes cause
classic CF (e.g., D1152H) and mutations that predispose to
congenital bilateral absence of the vas deferens even though
most compound heterozygotes are asymptomatic (e.g., 5T).
PSTI exons and flanking sequences were screened by dena-
turing high-performance liquid chromatography.17,18 N34S
Table 1. Subgroups of Subjects Based on Recruitment and Testing
Subgroups based on recruitment
39 Total number of subjects in study.
26 Number of subjects recruited for the initial study.4
For these, hereditary pancreatitis was excluded based on family history.
11 Number of subjects recruited using similar inclusion criteria after the initial study.
For these, hereditary pancreatitis was excluded based on PRSS1 genetic testing.
2 Number of subjects who were known to be CF carriers before referral.
These subjects were excluded from most prevalence ratio calculations.
Subgroups based on testing
39 Number of subjects screened for common CFTR, PSTI, and PRSS1 mutations.
20 Number of subjects who had comprehensive DNA sequencing of CFTR gene.
8 Subjects who had 1 CF-causing mutation found by screening.
8 Subjects who had only mild-variable (CFm-v) mutations identified by screening.
4 Subjects who had 2 apparently normal CFTR alleles based on screening.
11 Number of subjects who had physiologic and clinical testing (Table 4).
6 CFTR compound heterozygotes.
1 CF carrier.
4 Subjects with normal CFTR genotypes.
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heterozygotes and homozygotes were confirmed by sequencing
exon 3 and restriction enzyme digestion (HpyCH4 III); het-
erozygotes were further tested by sequencing the PSTI pro-
moter, exons, and flanking sequences. To estimate the general
prevalence of N34S, white patients with hemochromatosis or
fragile X were screened by denaturing high-performance liq-
uid chromatography and restriction enzyme digestion; N34S
occurred in 4 of 426 control alleles (0.9%).
For PRSS1, DNA was tested for R122H (“R117H”) by
restriction enzyme digestion15 and for A16V (“A8V”) and
N29I (“N21I”) by sequencing exon 2.19,20
Physiologic and Clinical Studies
Eleven subjects were selected for physiologic and clin-
ical evaluation based on their willingness to participate. Nasal
bioelectric responses were recorded to measure baseline poten-
tial differences and CFTR-mediated ion transport.21 Subjects
were clinically assessed for respiratory and male reproductive
findings. Laboratory studies included sweat testing, chest ra-
diographs, spirometry, and sputum culture. Subjects provided
separate informed consent for genetic and physiologic/clinical
testing.
Data Analysis
Groups were compared using the Fisher exact or un-
paired t tests. The exact test was used for comparisons yielding
prevalence ratios below 500 and the binomial distribution was
used for comparisons involving very rare events (with preva-
lence ratios over 500). Means (6 SEM) and 2-tailed P values
are presented.
Results
CFTR Mutations in Individual Subjects
Twenty-six CFTR mutations were detected in 17
subjects (Table 2). There were 21 common mutations; 9
were severe (CFsev: DF508, N1303K, 62111G.T) and
12 were mild-variable (CFm-v: 5T, R117H). Among the
9 subjects with severe mutations (nominal CF carriers), 3







complex allelesa PSTI PRSS1
1 45 M DF508/R117H-7T (Screened only) N34S/2 2/2
2 32 F DF508/5T 11TG-5T-V470; I1027T 2/2 2/2
3 48 F DF508/5T 12TG-5T-V470 2/2 2/2
4b 8 M DF508/D1152H D1152H-V470 2/2 2/2
5 15 F DF508/D1152H D1152H-V470 2/2 2/2
6 26 F DF508/P574H None 2/2 2/2
7 40 F DF508/3120G.A None 2/2 2/2
8b 16 M 62111G.T/G1069R None 2/2 2/2
9 7 F 5T/5T 13TG-5T/11TG-5T N34S/2 2/2
10 43 M N1303K/2 None 2/2 2/2
11 32 F R117H-7T/2 40051117T.G 2/2 2/2
12 33 M 5T/2 1716G.A/12TG-5T-V470 2/2 2/2
13 51 M 5T/2 11TG-5T 2/2 2/2
14 29 F 5T/2 None 2/2 2/2
15 12 F 5T/2 None 2/2 2/2
16 30 F 5T/2 1248115T.A/11TG-5T 2/2 2/2
17 14 M 5T/2 12TG-5T-V470 N34S/2 2/2
18 12 F 2/2 None N34S/N34S 2/2
19 46 F 2/2 R75Q N34S/2 2/2
20 44 F 2/2 None N34S/2 2/2
21 21 F 2/2 (Screened only) N34S/2 2/2
22 47 F 2/2 (Screened only) N34S/2 2/2
23 35 M 2/2 (Screened only) N34S/2 2/2
24 16 F 2/2 R75Q 2/2 R122H/2
NOTE. Thirty-nine ICP patients were screened for common CFTR, PSTI, and PRSS1 mutations. The CFTR mutation panel included DF508, R117H,
R334W, R347P, A455E, I507, G542X, S549N, G551D, R553X, R560T, D1152H, W1282X, N1303K, 62111G.T, 171721G.A, 3849110kb
C.T and the 5T allele in intron 8. Most CFTR mutation screening data was previously reported for 16 subjects: nos. 1–3, 5, 7, 10–12, 14, 15,
18, 19, and 21–24.4 Twenty subjects were tested for rare CFTR mutations by sequencing all exons and flanking regions (nos. 2–20 and 24). Eight
subjects were tested for rare PSTI mutations by sequencing all exons, flanking regions, and the promoter (nos. 1, 9, 17, and 19–23).
Dx, diagnosis.
aI1027T, R75Q, and 1716G.A are noted because they may be associated with congenital bilateral absence of the vas deferens.22,28 12481
15T.A is novel (significance unknown). Complex alleles cause greater loss of function than 5T alone (e.g., 13TG-5T, 12TG-5T, and 5T-V470).28
Mutations linked to V470 are noted because V470 reduces CFTR function by 40%.28 Six subjects were heterozygous for V470 with undetermined
linkage (nos. 10, 13–15, 19, and 24). All 20 sequenced subjects were tested for the above polymorphisms plus 2694T.G (T854T), 4521G.
A (Q1463Q), 405146G.T, 875140A.G, IVS6a(GATT)6-7, and 1001111C.T.
bBefore referral, subjects 4 and 8 were known to have the DF508 or 62111G.T mutations with normal or borderline sweat testing, respectively.
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had common milder CFTR mutations (nos. 1–3), 5 had
rare mutations that were detected by DNA sequencing
(nos. 4–8), and 1 had a normal second CFTR allele based
on DNA sequencing (no. 10). Each of the rare mutations
detected in subjects 4–8 is mild-variable: D1152H,
P574H, G1069R, and 3120G.A.22–25 No other rare
mutations were found in the remaining 11 subjects who
were tested by DNA sequencing.
Compound Heterozygotes
Nine subjects were compound heterozygotes.
Eight had CFsev/CFm-v genotypes (nos. 1–8) and 1 was
CFm-v/CFm-v (no. 9). None of the subjects had 2 severe
mutations, as anticipated, because individuals with CF
were excluded. Only 1 compound heterozygote’s geno-
type was detectable by routine genetic testing (no. 1).
Novel Mutations, Polymorphisms, and
Complex Alleles
One subject had a new mutation (no. 16;
1248115T.A; significance unknown). No polymor-
phism was especially frequent in pancreatitis; 3 of the
detected polymorphisms may predispose to male infer-
tility and might therefore be associated with partial loss
of CFTR function (I1027T, 1716G.A, R75Q).22,26,27
The 5T mutation often occurred in complex alleles (in
cis) that cause greater loss of function than 5T alone:
TG13-5T (no. 9), TG12-5T-V470 (nos. 3, 12, and 17),
and 5T-V470 (no. 2).28–31
CFTR Allele and Genotype Prevalences
Table 3 compares the observed versus expected
frequencies of CFTR alleles and genotypes in the series.
Pancreatitis is associated with severe mutations (5:1,
observed:expected ratio). However, the more striking
association is with CFsev/CFm-v genotypes (80:1).
Among the 9 subjects with severe mutations, 8 had
mild-variable mutations (16:1); only 1 CF carrier had a
normal allele (no. 10). Compound heterozygotes (nos.
1–9) accounted for most detected severe (8/9) and mild-
variable (10/17) mutations. After excluding compound
heterozygotes, pancreatitis was no longer significantly
associated with severe (1/29) or mild-variable (7/29)
mutations. There also was no association with 5T after
excluding subjects with complex alleles containing 5T
(4/33).





CFsev (severe) 1/57 7/74 5.3 [2.5–11.7], P 5 0.0006
CFm-v (mild-variable) 1/18 17/74 4.1 [2.6–6.5], P , 0.0001
5T (most common CFm-v) 1/20 10/74 2.6 [1.5–5.0], P , 0.005
Abnormal CFTR genotypes
Compound heterozygotes 1/204 7/37 39 [14–105], P , 0.0001
CFsev/CFm-v 1/509 6/37 83 [21–318], P , 0.0001
Abnormal PSTI alleles
N34S 11/1764 10/74 22 [10–49], P , 0.0001
In subjects Dx’d by age 21 ” 5/18 45 [17–115], P , 0.0001
In subjects Dx’d after age 21 ” 5/56 14 [5–40], P , 0.0001
CFTR compound heterozygote 1 N34S 1/16400 2/37 900, P , 0.0001
Subset analyses
CFm-v, if CFsev present 1/18 8/9 16 [13–20], P , 0.0001
N34S, if CFTR compound heterozygote 11/1764 2/18 18 [4–75], P 5 0.007
NOTE. Subject numbers and genotypes are listed in Table 2. Abnormal CFTR alleles cause either severe (CFsev) or mild-variable loss of function
(CFm-v). Observed:expected ratios and 95% confidence intervals (in brackets) were calculated by the Fisher exact test when possible. For ratios
over 500, P values were calculated using the binomial distribution.
Dx’d, diagnosed.
aThe expected frequency of mutations was estimated assuming that the frequency of CF in U.S. Whites is 1/3200,51 that the total allele
frequency for CFsev mutations is 1/32000.5, and that the allele frequencies for 5T and R117H are 5%23,24,52 and 0.2%,53,54 respectively. Allele
prevalence data is unavailable for other CFm-v alleles; in congenital bilateral absence of the vas deferens, their combined prevalence is less than
for R117H24,26,27 and we assumed that their combined prevalence in U.S. Whites is 0.4%. For the N34S PSTI mutation, the expected allele
frequency was calculated by combining data from 3 prior studies (7/1338 alleles, total)10,11,32 with data for control subjects in this study (4/426
alleles). To estimate expected frequencies containing multiple alleles, we assumed that each occurred independently (e.g., CFsev/CFm-v 5
(2)(1/18)(1/56.6) 5 1/509).
bA total of 26 abnormal CFTR alleles were detected among 78 tested alleles in 39 patients. However, because 2 subjects were known to have
CFsev mutations before enrollment (nos. 4 and 8), their data was excluded from most calculations to avoid ascertainment bias. These 2 subjects
were only included in the subset analyses at the bottom of the table.
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PSTI Mutations
The N34S PSTI mutation occurred in 10 of 78
alleles from study subjects (21:1; P , 0.0001). One
subject was N34S homozygous, and 8 were heterozygotes
with 1 verified normal PSTI allele. Thus, N34S carrier
status is sufficient to increase pancreatitis risk. Other
potential PSTI mutations (M1T, L14P, D50E, P55S,
IVS2-23A.T, and IVS312T.C)10,11,32 were absent.
Two of 9 CFTR compound heterozygotes with pan-
creatitis had N34S (18:1; P , 0.01). Assuming inde-
pendent inheritance of CFTR and PSTI genotypes, these
2 examples suggest that pancreatitis risk is increased
approximately 900-fold in N34S carriers who are CFTR
compound heterozygotes.
PRSS1 Mutations
The R122H PRSS1 mutation occurred in 1 sub-
ject who was enrolled when we were excluding hereditary
pancreatitis (pre-entry) based only on family history data
(no. 24). Anamnestic data for this subject indicated that
she had no relatives with pancreatitis. For subjects re-
cruited after 1996, hereditary pancreatitis was excluded
before entry by PRSS1 testing. Accordingly, R122H and
other known PRSS1 mutations were absent in all pa-
tients in the series other than no. 24.
Clinical and Physiologic Features
The mean age at diagnosis was 33.2 6 2.5 years
(n 5 39), and 11 subjects were diagnosed by age 21 years.
Subjects 2, 3, 4, and 8 each had 1 relative with pancre-
atitis. The affected sister of subject 8 had the genotype
62111G.T / G1069R; DNA was not available for the
other 3 affected relatives. Subjects with any mutation (no.
1–24) were younger than others at diagnosis (29.3 6 2.9 vs.
39.5 6 4.2; P , 0.05). Pancreatogram findings were
equally severe in subjects with or without mutations.
Table 4 compares physiologic data for the tested subjects
who had 0 vs. 2 CFTR mutations. Five of these subjects had
PSTI or PRSS1 mutations; the physiologic parameters were
unaffected by these mutations. (Subjects were selected for
physiologic testing before testing for PSTI mutations was
possible.) Baseline nasal potential difference (PD) values,
which reflect basal Na1 transport, were normal and did not
correlate with the number of CFTR mutations.
CFTR-Mediated Chloride Transport
DPD values (in mV) correlated with CFTR geno-
types in subjects with 0 vs. 2 mutations (Figure 1).
When compared with historical data,21 subjects with no
mutations resembled normal controls. In compound het-
erozygotes, CFTR-mediated chloride transport was lower
than in normal controls (P , 0.0001) or in subjects
without mutations (P , 0.01), but higher than in indi-
viduals with CF (P , 0.002).21
Sweat Testing
Sweat chloride values were normal in subjects
with normal CFTR genotypes who had PRSS1 or PSTI










PSTI or PRSS1 mutations, sputum
cultures, male fertility, etc.
1 47, M DF508/R117H 29 86 224 15.0 N34S/2, infertile,a smooth P. aeruginosa
2 34, F DF508/5T 59 106 215 11.5
3 53, F DF508/5T 62 78 210 21.0 FEV1 58% before subject stopped smoking
4 18, M DF508/D1152H 62 115 238 26.5 Palpable vas deferens
5 21, F DF508/D1152H 32 94 223 22.5
6 28, F DF508/P574H 81 109 225 ND S. aureus, S. maltophlia; sinus surgery
10 47, M N1303K/2 41 106 220 220 Palpable vas deferens
18 20, F 2/2 24 119 227 218 N34S/N34S
19 50, F 2/2 36b 31 213 217 N34S/2, 30 pack/year smoker
20 46, F 2/2 16 97 210 247 N34S/2
24 18, F 2/2 14 86 216 219.5 R122H cationic trypsinogen mutation
Mean values (6SEM) for groups based on CFTR genotypes
1–6 mutant/mutant 54 6 8c 98 6 6 223 6 4 20.7 6 1.9c
18–20 and 24 2/2 23 6 5 83 6 19 217 6 2 225.4 6 7.3
NOTE. Subject numbers and genotyping data are from Table 2. This table shows age at testing (not age at diagnosis). Each subject’s chest
radiograph was normal except for basilar linear atelectasis in no. 1 and hyperinflation in subjects 13 and 19. Some data was previously reported
for subjects 1–3.4 Subject 3 was retested after she stopped smoking. Other subjects were nonsmokers except as noted.
aSubject 1 was infertile because of congenital bilateral absence of the vas deferens. Subjects 4 and 10 had a palpable vas deferens and subject
10 had offspring.
bThis value is based on 1 measurement; other values are means of at least 2 sweat tests.
cSubjects with 2 CFTR mutations were significantly different from subjects with no mutations based on sweat CI2 and DPD values (P , 0.02 for
each comparison).
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mutations. By contrast, subjects with 2 CFTR mutations
had higher mean sweat chloride values (54 6 8, P ,
0.02). Even though these subjects each had at least 2
normal or borderline sweat chloride values in the past, 3
of them had values above 60 mmol/L when last tested
(Table 4).
Respiratory Findings
No subject had CF lung disease (Table 4). None-
theless, 2 compound heterozygotes produced sputum
containing CF-associated bacteria (nos. 1 and 6); in both,
spirometry was normal and bronchiectasis was absent.
One compound heterozygote (no. 6) had severe recurrent
sinusitis requiring a Caldwell-Luc procedure; others (nos.
1 and 3) had milder sinusitis.
Fertility in Males
One compound heterozygote had congenital bi-
lateral absence of the vas deferens (no. 1); another had a
palpable vas bilaterally (no. 4).
Features of the CF Carrier
One subject in the series was a CF carrier who had
1 normal CFTR allele based on DNA sequencing (no.
10). He had normal baseline and DPD values (Table 4),
as anticipated based on published data for obligate CF
carriers.33 He had a palpable vas deferens bilaterally, has
fathered children, and had no respiratory findings sug-
gesting reduced CFTR function.
Discussion
This study shows that idiopathic chronic pancre-
atitis is often associated with having 2 CFTR mutations
or 1 PSTI mutation. These genotypes occurred in many
cases diagnosed by age 50 years (16/32 after excluding
hereditary pancreatitis) and in most diagnosed by 21
years old (7/10). Pancreatitis risk was highest in those
with 2 CFTR mutations plus N34S.
For CFTR, the greatest risk of pancreatitis is associ-
ated with compound heterozygote genotypes containing
1 severe mutation plus 1 mild-variable mutation. The
mild-variable mutations in these genotypes account for
the residual CFTR function (5%–25%) that protects
these individuals from CF lung disease24 and that may
also be required for pancreatitis to occur.34 Because mild-
variable mutations are generally excluded from mutation
panels used for CF testing, routine genetic testing would
incorrectly classify most compound heterozygote pancre-
atitis patients as carriers; this explains why we found a
higher frequency of CFTR compound heterozygotes than
others who tested only for common mutations.5–9 Thus,
even though pancreatitis risk is increased in individuals
identified as carriers by routine genetic testing, more
complete testing of a series of such nominal carriers with
pancreatitis showed that most were compound heterozy-
gotes who had initially undetected mutations. This is the
main finding of the present study; it suggests autosomal
recessive inheritance for most CFTR-related pancreatitis
risk and implicates reduced CFTR function in pathogen-
esis.
A primary goal of this study was to thoroughly test a
series of subjects with pancreatitis who have common
CF-causing mutations to determine whether their second
CFTR allele contains an uncommon mutation that was
initially undetected. We tested for these uncommon
mutations by DNA sequencing because it is more sen-
sitive than the screening methods previously used to
study pancreatits4–9 and other nonpulmonary CFTR-
related diseases.22–26,35–37 Because some subjects in this
study (a minority) were not tested by DNA sequencing,
it is possible that our data underestimated the prevalence
of genotypes containing only mutations that were absent
in the mutation panel used for screening (e.g., CFm-v/
CFm-v genotypes).
This study found mild-variable CFTR mutations in
most pancreatitis patients with abnormal genotypes. The
predominant mild-variable mutation in pancreatitis was
Figure 1. CFTR function in the nasal epithelium in genotyped subjects
with pancreatitis. CFTR-mediated Cl2 conductance (DPD) was mea-
sured in subjects with pancreatitis who had 0 vs. 2 CFTR mutations,
and compared with published values for normal controls and for
individuals with classic cystic fibrosis.20 Subjects with CFTR-related
pancreatitis (i.e., those with 2 mutations) differed significantly from
subjects without CFTR mutations, from normal controls, and from
individuals with CF based on their DPD values (P , 0.01 for each
comparison). This indicates that these subjects had less CFTR-medi-
ated ion transport than normal but that this loss of function was less
severe than in cystic fibrosis. One study subject with a CF-causing
mutation had a normal second CFTR allele based on DNA sequencing;
his DPD value of 220 mV (not shown) was normal, as anticipated
based on published data for obligate CF carriers.32
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5T. This mutation causes inefficient splicing of exon 10
leading to production of nonfunctional copies of CFTR.38
5T occurred in 13% of pancreatitis alleles vs. 5% in the
general population and vs. 12%–20% in congenital bi-
lateral absence of the vas deferens.22,24,26 Our data con-
trasts with prior studies reporting no association of 5T
with pancreatitis.5–7,9 The higher 5T prevalence in our
study may partly result from including subjects with
juvenile-onset disease and excluding individuals report-
ing moderate alcohol use. In any case, our data suggests
that 5T-related pancreatitis risk is largely caused by 5T
occurring either in complex alleles28–31 or in CFTR
compound heterozygote genotypes. This study’s physio-
logic findings also correlate CFTR loss of function with
pancreatitis risk. CFTR-mediated chloride transport in
the nasal epithelium (DPD) was abnormal in compound
heterozygotes but normal in subjects without CFTR
mutations. Nonetheless, compound heterozygotes dif-
fered from CF patients in that their DPD values were less
abnormal and their baseline PD values were normal; both
findings reflect CFTR loss of function between that in CF
(.95%) and in carriers (50%). By contrast, the 1 CF
carrier in the series (no. 10) had a normal DPD value, as
is typical of obligate CF carriers.33 Because the preva-
lence of CF carriers was not increased in the series, this
individual may have been ascertained by chance, alone.
Finally, the link between pancreatitis risk and CFTR
loss of function is supported by extrapancreatic clinical
findings observed in compound heterozygotes. These are
reminiscent of findings associated with congenital bilat-
eral absence of the vas deferens23,25,26,35,36 and include
abnormal sweat testing, bronchitis with sputum contain-
ing CF-typical pathogens, and sinusitis. The absence of
CF lung disease was anticipated because no subject had 2
severe mutations24; the variable expression of vas deferens
disease was also anticipated based on the incomplete
penetrance of infertility in males with CFsev/CFm-v geno-
types (approximately 20%).39
There are many parallels between CFTR-related pancre-
atitis and congenital bilateral absence of the vas deferens.40
Both diseases are usually sporadic, delaying recognition
of their heritability. Both were initially associated with
CF carrier status; however, further study revealed their
closer association with compound heterozygosity and
with mild-variable mutations initially classified as be-
nign polymorphisms (e.g., 5T). As in congenital bilateral
absence of the vas deferens,39 there seems to be incom-
plete penetrance for pancreatitis in CFTR compound
heterozygotes, implicating gene-gene or gene-environ-
ment interactions in pathogenesis. In other words, since
most CFTR compound heterozygotes do not develop
pancreatitis, other genetic or environmental factors must
also be important in determining this phenotype.
More generally, the relationship between CF carrier
status and pancreatitis suggests a novel paradigm for
genetic predisposition in which mild mutations of a
recessive Mendelian disease gene (CFTR) increase the
risk of a seemingly unrelated disease (pancreatitis).40
Based on this example, we speculate that mild or atypical
mutations of other Mendelian disease genes may play
similar roles in other complex diseases.
For gastroenterologists, there also are pertinent paral-
lels between CFTR-related pancreatitis and some forms
of cholestasis with respect to genetic predisposition: The
liver resembles the pancreas in that CFTR occurs mainly
in the apical membranes of duct cells where it normally
promotes bicarbonate and fluid secretion into the duct
lumen.41–43 This suggests that reduced CFTR function
might predispose to hepatobiliary disease, and this sug-
gestion is supported by recent data associating reduced
nasal CFTR-mediated chloride transport with sclerosing
cholangitis.44
This study also examined how PSTI mutations influ-
ence pancreatitis risk. It was already known that having
the N34S PSTI mutation predisposes to childhood pan-
creatitis; even though most children with N34S do not
develop pancreatitis, the risk of pancreatitis is increased
in those who have this mutation.10,11 Our findings show
that this association also applies to adults with idiopathic
chronic pancreatitis.
We also found that N34S carrier status and CFTR
compound heterozygosity had additive effects on pancre-
atitis risk. Because subjects with only N34S (nos. 18–20)
had normal CFTR-mediated ion transport and no clinical
evidence of reduced extrapancreatic CFTR function, this
study’s genetic, physiologic, and clinical findings indi-
cate that PSTI and CFTR mutations act separately to
increase pancreatitis risk. One implication of these find-
ings is that intrapancreatic protease activation may con-
tribute to the pathogenesis of CFTR-related pancreatitis.
A related implication is that N34S carrier status may
help explain the occasional occurrence of pancreatitis in
individuals with CF or congenital bilateral absence of the
vas deferens.
The effect of PSTI and CFTR mutations on pancre-
atitis risk has important implications for pathogenesis
and prevention. Because PSTI and CFTR occur in acinar
and ductal cells, respectively, this effect identifies these
sites as distinct targets for interventions aiming to reduce
pancreatitis risk. Specifically, susceptible individuals
may benefit from promoting ductal bicarbonate secre-
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tion41 and from reducing intra-acinar trypsinogen acti-
vation.11
This study also has implications for clinical practice.
For PRSS1, we identified one apparently sporadic case of
hereditary pancreatitis in the series and 3 additional
sporadic cases were excluded among younger candidates
considered for this study. Current clinical practice relies
on family history data to identify potential cases of
hereditary pancreatitis,19,45,46 but the occurrence of such
sporadic cases implies that a negative family is not
sufficient to exclude the diagnosis of hereditary pancre-
atitis.
The frequency of CFTR, PSTI, and PRSS1 mutations
in chronic pancreatitis suggests that some patients with
this condition may benefit from genetic testing. Because
initial reports have not associated alcoholic pancreatitis
with these mutations,8,32,47,48 genetic testing may help
distinguish between alcohol-related and idiopathic cases;
detection of mutations may improve medical care and
patient satisfaction in cases where physicians might oth-
erwise suspect undisclosed alcoholism. Moreover, when
causative PRSS1 mutations are detected, the correct di-
agnosis is hereditary pancreatitis, a disease that differs
from idiopathic pancreatitis because it leads to pancreatic
adenocarcinoma with a cumulative risk approaching
40%.49 Surveillance may permit early cancer detection in
these individuals.
For CFTR, there is currently no consensus about the
role of genetic testing in idiopathic chronic pancreati-
tis.50 Even though current treatment for chronic pancre-
atitis is the same regardless of whether CFTR mutations
are found, some patients will wish to be tested so they
can better understand their disease. Others will wish to
know if they are carriers for CF before having children.
When CFTR genetic testing is done in pancreatitis
patients, the results will require cautious interpretation.
Rare pancreatitis patients will have 2 detected CFTR
mutations. This group will include patients with unrec-
ognized classic CF in whom pancreatitis precedes overt
lung disease; most will have diagnostic sweat tests and
may benefit from specialized pulmonary care. More often,
genetic testing will detect only 1 mutation. In these
cases, the presence of associated findings (borderline
sweat testing, male infertility, abnormal nasal bioelectric
responses, etc.) should suggest CFTR compound het-
erozygosity. In these cases, compound heterozygosity
might be confirmed by 5T testing; however, most such
cases will have mild-variable mutations that are unde-
tectable using widely available CFTR genetic testing
methods.
In summary, most patients with idiopathic chronic
pancreatitis had mutations of at least 1 tested gene.
Occasionally, pancreatitis occurred as a sporadic condi-
tion caused by PRSS1 mutations; more often, suscepti-
bility to pancreatitis resulted from CFTR compound
heterozygosity and PSTI carrier status. Genetic, clinical,
and physiologic data indicate that CFTR and PSTI mu-
tations influence pancreatitis risk through independent
mechanisms. Genetic testing may be useful in selected
patients with chronic pancreatitis.
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